FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula (I), where R1 is hydrogen or C1-C6alkyl; R2 is hydrogen and R3 is hydroxy(C1-C6)alkyl; or pharmaceutically acceptable salts thereof. The invention also relates to methods of producing compounds of formula (I), intermediate compounds given in paragraphs 14-19 of the claim, and a method of producing an intermediate compound according to paragraph 17 of the claim.
EFFECT: obtaining compounds of formula 
as PGD2 synthase inhibitors and intermediate compounds for production thereof.
20 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | 2006 |
|
RU2420519C2 |
| PIPERAZINE COMPOUND INHIBITING PROSTAGLANDIN-D-SYNTHASE | 2010 |
|
RU2496778C2 |
| PIPERIDINYLPYRAZOLOPYRIMIDINONES AND USE THEREOF | 2015 |
|
RU2713937C2 |
| PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | 2008 |
|
RU2464262C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-RICH REPEATING KINASE 2 (LRRK2) FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2647849C2 |
| NEW PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AND APPLICATION THEREOF | 2014 |
|
RU2621709C2 |
| 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINOPYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2007 |
|
RU2431631C2 |
| COMPOUND HAVING AGONISTIC ACTIVITY AGAINST GPR119, METHOD FOR ITS PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN EFFECTIVE COMPONENT | 2015 |
|
RU2670197C1 |
